Mortality Rate of Neurosarcoidosis
Neurosarcoidosis carries an approximately 10-11% mortality rate at 10 years, making it an important cause of death in sarcoidosis patients, with deaths occurring at younger ages compared to pulmonary sarcoidosis. 1, 2, 3
Key Mortality Data
The 2021 European Respiratory Society guidelines explicitly state that while most sarcoidosis deaths result from pulmonary disease, neurosarcoidosis represents an important cause of death, with mortality occurring at younger ages 1. A 2023 French study reported mortality of approximately 10% at 10 years 2, which aligns with data from a large retrospective cohort of 234 neurosarcoidosis patients showing a probable 10-year survival rate of 89% (95% CI, 84%-94%), translating to an 11% mortality rate 3.
Prognostic Factors Associated with Mortality
The following factors significantly increase mortality risk 3:
- Older age at diagnosis (hazard ratio 1.64 per 10 years; 95% CI, 1.19-2.27; P = .003)
- Peripheral nervous system involvement (hazard ratio 6.75; 95% CI, 2.31-19.7; P < .001)
- Higher baseline disability scores (hazard ratio 1.21 per EDSS point; 95% CI, 1.06-1.39; P = .005)
Morbidity Beyond Mortality
Beyond the mortality figures, more than 30% of neurosarcoidosis patients develop significant disability 2. The disease has a substantial impact on quality of life through various manifestations including facial nerve palsy, optic neuritis, aseptic meningitis, CNS mass lesions, hydrocephalus, and encephalopathy 1.
Clinical Implications
The relatively high mortality rate and young age at death underscore why the ERS guidelines make a strong recommendation for glucocorticoid treatment in clinically significant neurosarcoidosis, despite very low quality of evidence—the committee recognized that the high risk for significant irreversible neurologic loss and mortality warranted aggressive treatment 1.
Important caveat: These mortality figures represent the natural history and outcomes with current treatment approaches. Early recognition and aggressive immunosuppressive therapy (glucocorticoids, methotrexate, and biologics like infliximab for refractory cases) may improve outcomes, as immunosuppressive therapies have been associated with lower relapse rates 3.